Setting PAH treatment goals and expectations
When you decide to start your adult patient on treatment with UPTRAVI, it’s important to set goals and expectations with them.
Before starting UPTRAVI, remind your adult patient of the following:
- Anticipate a call from your specialty pharmacy to alert you of your next shipment of UPTRAVI
- Do not change your dose or stop taking UPTRAVI unless your doctor tells you to do so1
- Understand expectations for potential side effects. Follow up with your doctor if you have side effects that you cannot tolerate1
- Try to take UPTRAVI with food. This may help you tolerate the dose better if you are having side effects with UPTRAVI1
- After the dose adjustment phase, you will have found your personal maintenance dose of UPTRAVI. This will be the dose you continue to take on a regular basis, unless your doctor tells you otherwise1
UPTRAVI Dose Adjustment Phase helps meet individual adult patient needs1
Your adult patient's recommended starting dose is 200 mcg twice daily. UPTRAVI dosing is unique to each patient based on how their body responds and adjusts to treatment. The dose adjustment phase is how you find your patient's personal maintenance dose.
*Once daily for adult patients with moderate hepatic impairment (Child-Pugh class B) and co-administration with moderate CYP2C8 inhibitors (eg, clopidogrel, deferasirox, and teriflunomide). Increase in increments of 200 mcg once daily at weekly intervals.
- If a dose of UPTRAVI is missed, patients should take the missed dose as soon as possible unless the next dose is within the next 6 hours
- If treatment is missed for 3 days or more, restart UPTRAVI at a lower dose and then retitrate
After the dose adjustment phase1
Once each patient reaches their personal dose (maintenance), a single-tablet equivalent is prescribed BID. For adult patients, there are 8 different single-tablet strengths of UPTRAVI, each a unique color.
UPTRAVI offers a range of dose strengths to accommodate each adult patient’s personal maintenance dose
Alternate methods of administration for patients who cannot swallow tablets whole1
Apple or orange juice
UPTRAVI 100 mcg or 150 mcg film-coated tablets can be dispersed and administered in apple or orange juice. Do not disperse the tablet(s) in water or milk.
- Do not crush or split the tablet(s)
- At least 1 mL of juice per tablet is recommended
- Add the juice to the required number of tablet(s) per dosing schedule
- Wait for 5 minutes and then stir until the tablets are dispersed
- Administer the mixture immediately after dispersion
- Do not store tablets that are mixed with juice for later use
Soft foods
Alternatively, UPTRAVI 100 mcg and 150 mcg tablets can also be administered with soft foods such as yogurt, applesauce, or mashed banana.
- Cover the required number of tablets with soft food.
- Administer the mixture immediately
- To ensure no tablet residue is left, add more soft food and administer the contents immediately
- Do not store tablets that are mixed with soft food for later use
UPTRAVI Offers Oral Administration With Similar Efficacy at Every Dose Group in Adults1
Time to first disease progression event in GRIPHON by dose group3
Efficacy by dose group of UPTRAVI vs placebo3†:
- 40% RISK
REDUCTION(low dose: 200 mcg to 400 mcg)
HR 0.60 (95% CI: 0.41, 0.88) - 47% RISK
REDUCTION(medium dose: 600 mcg to 1000 mcg)
HR 0.53 (95% CI: 0.38, 0.72) - 36% RISK
REDUCTION(high dose: 1200 mcg to 1600 mcg)
HR 0.64 (95% CI: 0.49, 0.82)
UPTRAVI doses were achieved across the 3 prespecified groups in the GRIPHON trial‡
- 200 mcg to 400 mcg BID (low dose): 23% of patients (n=133)
- 600 mcg to 1000 mcg BID (medium dose): 31% of patients (n=179)
- 1200 mcg to 1600 mcg BID (high dose): 43%
of patients (n=246)
No needles, pumps, or inhalers1§
